Editing Brain tumor (section)

===Chemotherapy===
Patients undergoing [[chemotherapy]] are administered drugs designed to kill [[tumor]] cells.<ref name="aans"/> Although chemotherapy may improve overall survival in patients with the most malignant primary brain tumors, it does so in only about 20 percent of patients. Chemotherapy is often used in young children instead of radiation, as radiation may have negative effects on the developing brain. The decision to prescribe this treatment is based on a patient's overall health, type of tumor, and extent of cancer. The toxicity and many side effects of the drugs, and the uncertain outcome of chemotherapy in brain tumors puts this treatment further down the line of treatment options with surgery and radiation therapy preferred.<ref>{{cite journal | vauthors = Perkins A, Liu G | title = Primary Brain Tumors in Adults: Diagnosis and Treatment | journal = American Family Physician | volume = 93 | issue = 3 | pages = 211–217 | date = February 2016 | pmid = 26926614 }}</ref>

UCLA Neuro-Oncology publishes real-time survival data for patients with a diagnosis of glioblastoma. They are the only institution in the United States that displays how brain tumor patients are performing on current therapies. They also show a listing of chemotherapy agents used to treat high-grade glioma tumors.<ref>{{cite web |publisher=UCLA Neuro-Oncology Program |url=http://www.neurooncology.ucla.edu/Performance/GlioblastomaMultiforme.aspx |title=How Our Patients Perform: Glioblastoma Multiforme |access-date=5 June 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120609070823/http://www.neurooncology.ucla.edu/Performance/GlioblastomaMultiforme.aspx |archive-date=9 June 2012  }}</ref>

Genetic mutations have significant effects on the effectiveness of chemotherapy. Gliomas with [[IDH1]] or [[IDH2]] mutations respond better to chemotherapy than those without the mutation. Loss of chromosome arms 1p and 19q also indicate better response to chemoradiation.<ref name=":4" />